Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mercury Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$8,914,213

540 payments

Through program year 2025, Mercury Clinical Research is reported as receiving $8,914,213 in research payments, across 540 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $378,831 69
2024 Research $313,487 92
2023 Research $817,456 99
2022 Research $1,099,920 80
2021 Research $3,745,889 97
2020 Research $2,219,204 65
2019 Research $339,427 38

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $5,293,534 115 payments
  2. Sanofi Pasteur Inc. $2,145,229 163 payments
  3. GlaxoSmithKline, LLC. $755,919 133 payments
  4. AstraZeneca Pharmaceuticals LP $312,786 18 payments
  5. Novo Nordisk AS $153,970 69 payments
  6. Cue Health Inc. $111,979 1 payment
  7. Takeda Pharmaceuticals U.S.A., Inc. $83,268 26 payments
  8. Sanofi US Services Inc. $44,062 10 payments
  9. Janssen Research & Development, LLC $13,000 2 payments
  10. Merck Sharp & Dohme Corporation $465 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $3,435,204 57 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $1,227,413 31 payments
  3. Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $988,440 81 payments
  4. MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $712,754 38 payments
  5. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $607,470 16 payments
  6. A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $278,400 50 payments
  7. AstraZeneca is developing mAbs to the SARS CoV 2 spike protein. The SARS CoV 2 spike protein contains the virus RBD which enables the virus to bind to receptors on human cells. By targeting this region of the virus spike protein antibodies can block the virus attachment to human cells and therefore is expected to block infection. Amino acid substitutions have been introduced into the antibodies to both extend their half lives which should prolong their potential prophylactic benefit and decrease $245,117 12 payments
  8. A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States $239,497 20 payments
  9. A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T $179,404 37 payments
  10. A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Studyto $163,778 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record